Transcriptome profiling reveals degree of variability in induced pluripotent stem cell lines: Impact for human disease modeling

Cellular Reprogramming

Volumn 17, Issue 5, 2015, Pages 327-337

  Schuster, Jens ^a   Halvardson, Jonatan ^a   Pilar Lorenzo, Laureanne ^a   Ameur, Adam ^a   Sobol, Maria ^a   Raykova, Doroteya ^a   Annerén, Göran ^a   Feuk, Lars ^a   Dahl, Niklas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA III TUBULIN; BETA TUBULIN; CELL SURFACE PROTEIN; LENTIVIRUS VECTOR; SMOOTH MUSCLE ACTIN; STAGE SPECIFIC EMBRYO ANTIGEN 3; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRA 1 60 PROTEIN; TRA 1 81 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ADHESION; CELL CLONE; CELL DIFFERENTIATION; CELL DIFFERENTIATION ASSAY; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; DISEASE MODEL; ECTODERM; EMBRYO; EMBRYOID BODY; EMBRYONIC STEM CELL; ENDODERM; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; KARYOTYPE; MALE; NORMAL HUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL LINE; PRIORITY JOURNAL; RNA PROCESSING; RNA SEQUENCE; RNA TRANSPORT; SPLICEOSOME; BIOLOGICAL MODEL; CELL LINE; CLUSTER ANALYSIS; CYTOLOGY; DISEASES; GENE EXPRESSION PROFILING; INDUCED PLURIPOTENT STEM CELL; METABOLISM;

ADULT; CELL DIFFERENTIATION; CELL LINE; CLUSTER ANALYSIS; DISEASE; EMBRYOID BODIES; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MODELS, BIOLOGICAL;

EID: 84942525145     PISSN: 21524971     EISSN: 21524998     Source Type: Journal    
DOI: 10.1089/cell.2015.0009     Document Type: Article

References (38)

1. Abyzov, A., Mariani, J., Palejev, D., Zhang, Y., Haney, M.S., Tomasini, L., Ferrandino, A.F., Rosenberg Belmaker, L.A., Szekely, A., Wilson, M., Kocabas, A., Calixto, N.E., Grigorenko, E.L., Huttner, A., Chawarska, K., Weissman, S., Urban, A.E., Gerstein, M., and Vaccarino, F.M. (2012). Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 492, 438-442.
2. Adewumi, O., Aflatoonian, B., Ahrlund-Richter, L., Amit, M., Andrews, P.W., Beighton, G., Bello, P.A., Benvenisty, N., Berry, L.S., Bevan, S., Blum, B., Brooking, J., Chen, K.G., Choo, A.B., Churchill, G.A., Corbel, M., Damjanov, I., Draper, J.S., Dvorak, P., Emanuelsson, K., Fleck, R.A., Ford, A., Gertow, K., Gertsenstein, M., Gokhale, P.J., Hamilton, R.S., Hampl, A., Healy, L.E., Hovatta, O., Hyllner, J., Imreh, M.P., Itskovitz-Eldor, J., Jackson, J., Johnson, J.L., Jones, M., Kee, K., King, B.L., Knowles, B.B., Lako, M., Lebrin, F., Mallon, B.S., Manning, D., Mayshar, Y. (2007). Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat. Biotechnol. 25, 803-816.
3. Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq-A Python framework to work with high-Throughput sequencing data. Bioinformatics 31, 166-169.
4. Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller, M., Croft, G.F., Amoroso, M.W., Oakley, D.H., Gnirke, A., Eggan, K., and Meissner, A. (2011). Reference maps of human ES and iPS cell variation enable high-Throughput characterization of pluripotent cell lines. Cell 144, 439-452.
5. Boue, S., Paramonov, I., Barrero, M.J., and Izpisua Belmonte, J.C. (2010). Analysis of human and mouse reprogramming of somatic cells to induced pluripotent stem cells. What is in the plate? PloS One 5, e12664.
6. Buganim, Y., Faddah, D.A., Cheng, A.W., Itskovich, E., Markoulaki, S., Ganz, K., Klemm, S.L., van Oudenaarden, A., and Jaenisch, R. (2012). Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 150, 1209-1222.
7. Cao, S., Loh, K., Pei, Y., Zhang, W., and Han, J. (2012). Overcoming barriers to the clinical utilization of iPSCs: Reprogramming efficiency, safety and quality. Protein Cell 3, 834-845.
8. Chen, H., Qian, K., Du, Z., Cao, J., Petersen, A., Liu, H., Blackbourn, L.W.t., Huang, C.L., Errigo, A., Yin, Y., Lu, J., Ayala, M., and Zhang, S.C. (2014). Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 14, 796-809.
9. Ebert, A.D., Yu, J., Rose, F.F., Jr., Mattis, V.B., Lorson, C.L., Thomson, J.A., and Svendsen, C.N. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280.
10. Gaspard, N., and Vanderhaeghen, P. (2011). From stem cells to neural networks: Recent advances and perspectives for neurodevelopmental disorders. Dev. Med. Child Neurol. 53, 13-17.
11. Hamada, M., Malureanu, L.A., Wijshake, T., Zhou, W., and van Deursen, J.M. (2012). Reprogramming to pluripotency can conceal somatic cell chromosomal instability. PLoS Genet. 8, e1002913.
12. Hansson, J., Rafiee, M.R., Reiland, S., Polo, J.M., Gehring, J., Okawa, S., Huber, W., Hochedlinger, K., and Krijgsveld, J. (2012). Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep. 2, 1579-1592.
13. Holm, S. (2008). Time to reconsider stem cell ethics-The importance of induced pluripotent cells. J. Med. Ethics 34, 63-64.
14. Inoue, H., and Yamanaka, S. (2011). The use of induced pluripotent stem cells in drug development. Clin. Pharmacol. Ther. 89, 655-661.
15. Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., Takahashi, K., Asaka, I., Aoi, T., Watanabe, A., Watanabe, K., Kadoya, C., Nakano, R., Watanabe, D., Maruyama, K., Hori, O., Hibino, S., Choshi, T., Nakahata, T., Hioki, H., Kaneko, T., Naitoh, M., Yoshikawa, K., Yamawaki, S., Suzuki, S., Hata, R., Ueno, S., Seki, T., Kobayashi, K., Toda, T., Murakami, K., Irie, K., Klein, W.L., Mori, H., Asada, T., Takahashi, R., Iwata, N., Yamanaka, S., and Inoue, H. (2013). Modeling Alzheimers disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12, 487-496.
16. Lo, B., and Parham, L. (2009). Ethical issues in stem cell research. Endocr. Rev. 30, 204-213.
17. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
18. Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D., and Woolf, P.J. (2009). GAGE: Generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 10, 161.
19. Meisner, L.F., and Johnson, J.A. (2008). Protocols for cytogenetic studies of human embryonic stem cells. Methods 45, 133-141.
20. Miller, J.D., Ganat, Y.M., Kishinevsky, S., Bowman, R.L., Liu, B., Tu, E.Y., Mandal, P.K., Vera, E., Shim, J.W., Kriks, S., Taldone, T., Fusaki, N., Tomishima, M.J., Krainc, D., Milner, T.A., Rossi, D.J., and Studer, L. (2013). Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691-705.
21. Mills, J.A., Wang, K., Paluru, P., Ying, L., Lu, L., Galvao, A.M., Xu, D., Yao, Y., Sullivan, S.K., Sullivan, L.M., Mac, H., Omari, A., Jean, J.C., Shen, S., Gower, A., Spira, A., Mostoslavsky, G., Kotton, D.N., French, D.L., Weiss, M.J., and Gadue, P. (2013). Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines. Blood 122, 2047-2051.
22. Mou, X., Wu, Y., Cao, H., Meng, Q., Wang, Q., Sun, C., Hu, S., Ma, Y., and Zhang, H. (2012). Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res. Ther. 3, 14.
23. Muraro, M.J., Kempe, H., and Verschure, P.J. (2013). Concise review: The dynamics of induced pluripotency and its behavior captured in gene network motifs. Stem Cells 31, 838-848.
24. Ohnuki, M., Takahashi, K., and Yamanaka, S. (2009). Generation and characterization of human induced pluripotent stem cells. Curr. Protoc. Stem Cell Biol. Chapter 4, Unit 4A 2.
25. Polo, J.M., Anderssen, E., Walsh, R.M., Schwarz, B.A., Nefzger, C.M., Lim, S.M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., Bar-Nur, O., Cheloufi, S., Stadtfeld, M., Figueroa, M.E., Robinton, D., Natesan, S., Melnick, A., Zhu, J., Ramaswamy, S., and Hochedlinger, K. (2012). A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 151, 1617-1632.
26. Prilutsky, D., Palmer, N.P., Smedemark-Margulies, N., Schlaeger, T.M., Margulies, D.M., and Kohane, I.S. (2014). iPSCderived neurons as a higher-Throughput readout for autism: promises and pitfalls. Trends Mol. Med. 20, 91-104.
27. Pruitt, K.D., Tatusova, T., and Maglott, D.R. (2007). NCBI reference sequences (RefSeq): A curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 35, D61-D65.
28. Reinhardt, P., Glatza, M., Hemmer, K., Tsytsyura, Y., Thiel, C.S., Hoing, S., Moritz, S., Parga, J.A., Wagner, L., Bruder, J.M., Wu, G., Schmid, B., Ropke, A., Klingauf, J., Schwamborn, J.C., Gasser, T., Scholer, H.R., and Sterneckert, J. (2013). Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PloS One 8, e59252.
29. Rooney, D., and Czepulski, B. (1992). Human Cytogenetics. A Practical Approach. (Oxford
30. Smith, K.P., Luong, M.X., and Stein, G.S. (2009). Pluripotency: Toward a gold standard for human ES and iPS cells. J. Cell. Physiol. 220, 21-29.
31. Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., Isacson, O., and Jaenisch, R. (2009). Parkinsons disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-977.
32. Sommer, C.A., Stadtfeld, M., Murphy, G.J., Hochedlinger, K., Kotton, D.N., and Mostoslavsky, G. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27, 543-549.
33. Sommer, C.A., and Mostoslavsky, G. (2013). The evolving field of induced pluripotency: Recent progress and future challenges. J. Cell. Physiol. 228, 267-275.
34. Staerk, J., Dawlaty, M.M., Gao, Q., Maetzel, D., Hanna, J., Sommer, C.A., Mostoslavsky, G., and Jaenisch, R. 2010 Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 7, 20-24.
35. Sturn, A., Quackenbush, J., and Trajanoski, Z. (2002). Genesis: Cluster analysis of microarray data. Bioinformatics 18, 207-208.
36. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
37. Vaskova, E.A., Stekleneva, A.E., Medvedev, S.P., and Zakian, S.M. (2013). Epigenetic memory phenomenon in induced pluripotent stem cells. Acta Naturae 5, 15-21.
38. Vitale, A.M., Matigian, N.A., Ravishankar, S., Bellette, B., Wood, S.A., Wolvetang, E.J., and Mackay-Sim, A. (2012). Variability in the generation of induced pluripotent stem cells: Importance for disease modeling. Stem Cells Transl. Med. 1, 641-650.